Table 1. Patients’ characteristics in the inflammation- and corticosteroid-induced ocular hypertension groups.
| Inflammation | Corticosteroid | P | ||
|---|---|---|---|---|
| Number of eyes (people) | 20 (16) | 16 (11) | ||
| Male/female (people) | 5/11 | 6/5 | ||
| Mean age (years) | 62.1 ± 13.2 | 63.0 ± 15.2 | 0.36* | |
| Mean observation duration (months) | 5.2 ± 3.0 | 5.2 ± 2.7 | 0.43* | |
| Mean BCVA (logMAR) | 0.47 ± 0.82 | 0.48 ± 0.80 | 0.44* | |
| Diagnosis of uveitis (eyes) | ||||
| Scleritis-associated uveitis | 5 | 2 | ||
| Behçet's disease | 6 | |||
| Herpes uveitis | 3 | |||
| Sarcoidosis | 2 | 1 | ||
| Vogt–Koyanagi–Harada disease | 2 | |||
| Cytomegalovirus-associated uveitis | 1 | |||
| Unknown | 9 | 5 | ||
| Prescribed anti-glaucoma agents | ||||
| Prostaglandin analogues | 15 | 13 | 0.71# | |
| β-blockers | 12 | 9 | ||
| Carbonic anhydrase inhibitors | 7 | 5 | ||
| α2-agonists | 5 | 8 | ||
*: analysed by the Mann–Whitney U-test
#: analysed by the chi-square test with Fisher’s test; BCVA, best-corrected visual acuity